Ofran

Quick links to important sections

Ofran

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ofran

Property Description
Active ingredient Ondansetron
Forms Tablet, Oral Solution, Injection
Pharmacological class Selective Serotonin 5-HT3 Receptor Antagonist
Common purpose Preventing Nausea and Vomiting
Origin Synthetic Compound

Ofran is a specific medicinal preparation containing the active ingredient Ondansetron, a synthetic compound classified as a potent antiemetic drug. Its identity is defined by its precise mechanism as a selective Serotonin 5-HT3 receptor antagonist. This classification means the prescription medicine works by interfering precisely with the body's neurochemical processes that initiate nausea and vomiting.

The Ondansetron formulation is clinically recognized for its targeted efficacy against emetic signals, particularly in situations where high levels of Serotonin are released in the gut and brain. This action is associated with pharmacological observations of the significant role of 5-HT3 antagonists in counteracting these pathways. This high degree of selectivity is a key differentiating factor, making the medicine effective at neutralizing the body’s primary emetic triggers without the broad sedative effects associated with some older antiemetic classes.

Composition, Forms, and General Purpose

Ofran is a single-ingredient product, with its effects directly linked to the properties of Ondansetron, typically formulated as the hydrochloride salt. The overall general purpose of Ofran is the reliable prevention and management of symptoms associated with nausea and vomiting.

Ondansetron is manufactured in several distinct dosage forms to accommodate various patient states and routes of administration, including the oral route via standard tablets and oral solution, and the parenteral routes of intravenous (IV) or intramuscular (IM) injection. These available pharmaceutical preparations, which include rapidly dissolving Oral Disintegrating Tablets (ODTs), ensure the flexibility required to deliver the antiemetic action efficiently, confirming its status as an essential medicine.

Regulatory References

  1. MedlinePlus
  2. U.S. National Institutes of Health
  3. World Health Organization (WHO)

What side effects are possible with Ofran?

Possible Side Effects and Safety Information

The safety profile of Ofran (Ondansetron) is established through regulatory classifications that categorize possible adverse reactions based on their frequency and impact on physiological systems. This information is derived exclusively from government regulatory sources such as the EMA and FDA.

Frequency-Classified Adverse Reactions

The following is a breakdown of commonly cited side effects based on regulatory frequency frameworks:

Classification Examples of Adverse Reactions (SOC)
Very Common Headache
Common Constipation, Sensation of warmth or flushing
Uncommon Seizures, Arrhythmias, Bradycardia, Hypotension, Transient increases in liver function tests
Rare QTc prolongation (potentially leading to Torsade de Pointes), Anaphylaxis, Transient visual disturbances

Serious Adverse Reactions and Safety Constraints

The official labeling notes several serious reactions and important safety limitations. Serious adverse reactions documented in regulatory sources include QT interval prolongation and the associated risk of a potentially fatal ventricular arrhythmia, Torsade de Pointes. Severe hypersensitivity reactions, including anaphylaxis, are also officially listed as a rare risk. Post-marketing reports have noted cases of Serotonin Syndrome, particularly when the medicine is used in combination with other serotonergic agents, and Myocardial Ischemia.

Ofran is contraindicated for use with Apomorphine due to the documented risk of profound hypotension and loss of consciousness. Caution is officially advised in patients with existing cardiac conditions or electrolyte abnormalities that could increase the risk of QTc prolongation. Furthermore, the medicine's antiemetic effect may mask symptoms of a progressive ileus or gastric distension, especially in patients following abdominal surgery or specific chemotherapy cycles.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific risks associated with Ofran (ondansetron) overdose, emphasizing the need for immediate medical attention if an accidental excess amount is used.

Documented Overdose Symptoms

Symptoms that have been reported following an overdose include sudden, transient blindness (amaurosis), severe constipation, and hypotension (low blood pressure). An ECG abnormality, specifically a second-degree atrioventricular block, has also been documented in overdose cases.

Dose-Related Risks and Cardiac Safety

Regulatory authorities have addressed a critical dose-related risk: a single intravenous dose of 32 mg of ondansetron is no longer recommended and has been withdrawn. This high dose was associated with a significant risk of QT interval prolongation, which can lead to a serious, potentially fatal abnormal heart rhythm known as Torsade de Pointes. The maximum recommended single intravenous dose is now 16 mg.

Immediate Emergency Action Required

If you believe that too much Ofran has been used, you must get medical help right away or contact a Poison Control center immediately. Emergency services (such as 911) must be called immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Ofran

What Ofran Treats: Main Uses and Benefits

Ofran is commonly used to help manage symptoms that interfere with daily functioning and create noticeable physiological strain, primarily by providing supportive relief against emetic episodes. This medication is applied in clinical settings that involve acute or disruptive symptom patterns, such as those arising from specific medical interventions. Its primary therapeutic application is for the prevention of symptoms linked to specific triggers.

The core use of Ofran is to address the sudden appearance and fluctuation of nausea, vomiting, and retching associated with three main condition categories: highly or moderately emetogenic chemotherapy, specific types of radiation therapy, and postoperative nausea and vomiting (PONV) in surgical patients.

This supportive application generally assists patients to cope more steadily and supports a sense of stability during difficult treatment cycles. The supportive use helps ease the overall symptom burden, which may contribute to improved comfort and supports general well-being during symptomatic phases.

“This medication is applied across domains where additional symptomatic support is needed to manage symptoms that interfere with daily comfort.”

Quick Fact: Relief for Acute Emetic Episodes

Ofran is relevant when short-term symptomatic assistance may be appropriate to help manage the physical and subjective distress of emesis, particularly in acute contexts such as recovery from general anesthesia or during oncology treatment cycles.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Ofran (Ondansetron)

Official regulatory documents define strict criteria for the use of Ofran, classifying populations as either contraindicated (must not use) or requiring conditional use.

Contraindications and Absolute Exclusions

Category Official Restriction Statement
Allergies Known hypersensitivity to Ondansetron or any component of the formulation.
Drug-Drug Interaction Concomitant use with Apomorphine (a Parkinson's medication) is strictly prohibited.
Cardiac Conditions Patients with a known history of congenital long QT syndrome.
Specific Formulation Oral disintegrating tablets (ODT) are contraindicated for patients with phenylketonuria (PKU).

Populations Requiring Restriction or Special Consideration

Eligibility is limited or conditional in the following groups:

  • Severe Hepatic Impairment: Patients with severe liver disease must have their total daily dose restricted (typically not to exceed 8 mg/day).
  • Cardiovascular Risk: Patients with conditions like congestive heart failure or electrolyte abnormalities (e.g., hypokalemia) require ECG monitoring if use is necessary.
  • Pregnancy and Lactation: Use during pregnancy is advised only if the benefit outweighs potential risk, as human safety data is limited. Breastfeeding is not recommended as the drug is known to pass into animal milk.
  • Age-Related Use: Safety and efficacy are not established for Ofran use in infants younger than certain ages (e.g., under 4 years for chemotherapy-induced nausea and vomiting).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ofran may interact with various medicinal products, including prescription and over-the-counter (OTC) medicines, leading to potential safety issues. Officially documented information emphasizes specific drug and drug class combinations that require caution or are contraindicated.


Documented Interaction Profile

Interacting Product Category Key Constraint or Requirement
Apomorphine Contraindicated due to risk of profound hypotension and loss of consciousness.
Serotonergic Drugs (e.g., SSRIs, SNRIs, Tramadol, Fentanyl) Increased risk of Serotonin Syndrome when used concomitantly.
QT-Prolonging Drugs Caution is advised; requires monitoring due to the potential for an additive effect on QT interval prolongation.
CYP450 Enzyme Inducers (e.g., Phenytoin, Carbamazepine, Rifampicin) May decrease the systemic exposure of Ofran, potentially reducing effectiveness.

Clinical and Procedural Constraints

Patients taking Ofran concomitantly with other QT-prolonging medicines or those with underlying cardiac conditions such as congestive heart failure or bradyarrhythmias may require Electrocardiogram (ECG) monitoring. Furthermore, the use of Ofran is generally avoided in patients with congenital long QT syndrome or uncorrected electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia). These constraints are mandated by regulatory agencies to manage the risks associated with altered cardiac function and central nervous system effects during co-administration.

Mechanism of Action

The mechanism of action of Ondansetron (Ofran) is based on its interaction with the Serotonin 5-HT3 Receptor. The molecule acts as a highly selective competitive antagonist, binding to the receptor site and preventing the endogenous neurotransmitter Serotonin (5-HT) from initiating cellular signaling. This action chemically silences the associated ligand-gated ion channel.

The mechanism is dual-acting, engaging both peripheral and central domains. Peripherally, the molecule blocks 5-HT3 receptors concentrated on vagal afferent nerve terminals in the gastrointestinal (GI) tract. Centrally, it blocks 5-HT3 receptors within the brain's Chemoreceptor Trigger Zone (CTZ). This dual intervention modifies early molecular steps that shape systemic physiological outcomes by blocking the afferent signal before it can activate the medullary center for emesis.

The high selectivity of the mechanism means its action is constrained to pathways where 5-HT3 signaling is dominant, and it lacks influence over parallel emetic cascades mediated by other transmitter systems, such as Dopamine (D2) or Neurokinin 1 (NK1) pathways.

Dosage and Administration Information

How Ofran is Used

Ofran (Ondansetron) is administered according to a standardized, event-dependent protocol based strictly on the triggering medical procedure, such as chemotherapy, radiation, or surgery. The medicine utilizes three officially approved routes of administration: oral (using tablets, solution, or Oral Disintegrating Tablets), intravenous (IV) injection or infusion, and intramuscular (IM) injection.

The dosing is designed for prophylaxis and must be initiated at a specific time before the anticipated emetic event. For procedures associated with high emetic risk, the standard is a single 24 mg oral dose. For events with lower risk, the typical regimen begins with 8 mg orally, followed by subsequent doses taken up to twice daily for a short course of up to five days to manage delayed effects. The medication is permitted to be taken with or without food.

Specific technical requirements govern administration. IV doses intended for prophylaxis must be appropriately diluted in standard solutions and delivered slowly over a period of at least 15 minutes. The maximum single intravenous dose is established at 16 mg. Furthermore, strict dosage constraints apply based on physiological status: the total daily dose for individuals with severe hepatic impairment is reduced and should not exceed 8 mg.

Recent Clinical Evidence

Research evidence / Overview of studies for Ofran (Ondansetron)


Evidence for Preventing Nausea and Vomiting from Cancer Treatment

Research exploring how symptoms change over time when Ofran is used in the context of acute physical discomfort associated with cancer treatments, specifically chemotherapy and radiation therapy. The evidence base here is primarily made up of Randomized Controlled Trials (RCTs) and systematic reviews, which allow researchers to explore how symptoms are measured in Ofran groups compared to control groups or other anti-sickness medicines.

Evidence in Chemotherapy-Induced Nausea and Vomiting (CINV)

Studies were conducted during periods of increased symptom activity—the hours and days following chemotherapy—for both highly and moderately emetogenic regimens. Research examined outcomes related to physical discomfort, such as the total absence of vomiting and the need for rescue medication (a measure called complete response). Studies reported measurements of complete response rates that tracked differently when Ofran was used. The research provides context for the symptom changes measured during the study period; however, long-term outcomes are not well characterized, and results apply only to the populations studied under those specific conditions.

Evidence in Radiation-Induced Nausea and Vomiting (RINV)

Ofran was evaluated in studies examining symptom intensity or variability associated with specific radiation therapy treatments. Research explored short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort. The volume of evidence available for RINV is less extensive than the evidence base for CINV, and the trial populations in these studies were often heterogeneous.


Evidence for Preventing Postoperative Nausea and Vomiting (PONV)

Ofran was studied for conditions associated with acute or disruptive episodes following surgical procedures performed under general anesthesia. Studies included extensive RCTs that monitored patient-reported outcomes describing perceived discomfort. Research describes measured differences in symptom activity in the observed populations during the short-term observation period, typically the first 24 hours after the operation. However, follow-up durations were limited, as the research primarily focuses on this immediate acute recovery period.


Evidence in Specialized or At-Risk Populations

Research has been conducted to understand the study context for Ofran in specific age groups and conditions, including pediatric patients and those with pregnancy-related nausea and vomiting (hyperemesis gravidarum). For children, studies tracked the frequency of vomiting episodes and the need for intravenous (IV) hydration in the emergency setting. For pregnancy, observational studies explored outcomes related to physiological strain and functional imbalance, but some large-scale reports have yielded mixed findings concerning a potential association with specific fetal outcomes, advising caution regarding use in the first trimester.


Limitations, Uncertainties, and Research Gaps

Limitations noted by authorities include inconsistent findings in large-scale observational studies (e.g., in pregnancy), limited long-term follow-up data in primary prevention trials, and data for certain subgroups (e.g., acute gastroenteritis) remaining insufficient regarding outcomes beyond the immediate acute phase.

Key Studies & References

  1. The preventive effects of ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov
  2. Cost-effectiveness of oral ondansetron for children with acute gastroenteritis in primary care: a randomised controlled trial
  3. Ondansetron - StatPearls - NCBI Bookshelf - NIH (General efficacy and regulatory overview)

Frequently Asked Questions (FAQ)

Common questions about Ofran (FAQ)

Q: Does Ofran have a generic version available?

Yes, the US Food and Drug Administration (FDA) has approved and maintains listings for generic versions of Ondansetron. Ondansetron is the active ingredient in Ofran.

Q: Is Ofran the same as [Commonly confused drug name]?

Ondansetron is the active pharmaceutical ingredient and the drug’s generic name. According to official information, Ofran is a specific medicinal preparation or brand name that contains Ondansetron.

Q: Can I buy Ofran over the counter?

No, Ofran (Ondansetron) is classified by regulatory authorities as a Human Prescription Drug. It requires a prescription from a licensed healthcare provider for dispensing.

Q: Can Ofran make you sleepy?

Official adverse event reports indicate that side effects such as drowsiness or sedation have occurred. Official information advises patients to be mindful of how the medicine may affect them before engaging in activities that require full attention.

Q: Is it normal to feel a bit dizzy after starting Ofran?

Yes, dizziness is listed in the official documents as a commonly reported side effect. This sensation can occur, especially during or immediately following rapid administration of the intravenous (IV) form.

Q: Can Ofran affect your mood?

Studies and official information indicate that certain psychological effects have been reported. These include side effects like agitation, anxiety, and other mood changes.

Q: How long does it usually take for Ofran to start working?

Regulatory information indicates that for the oral form, the medication typically reaches its peak concentration in the blood within 0.5 to 2 hours after a dose.

Q: Are there any foods or drinks I need to avoid while on Ofran?

Ofran may be taken with or without food. However, official information suggests caution regarding substances that affect the serotonin pathway, such as grapefruit juice, as interactions may increase the risk of Serotonin Syndrome.

Q: Can Ofran be taken at the same time as vitamins or supplements?

Regulatory guidance notes that patients should inform their healthcare provider about all substances used, including supplements, due to the potential for interaction. This is because some herbal products or supplements may affect the liver enzymes (CYP450) that process Ofran in the body.

Q: Can older adults use Ofran safely?

No specific dosage adjustment is generally required for the geriatric population, however, regulatory documents note that its use requires consideration of the patient's existing health conditions, such as those affecting the heart or liver function.

Q: What is the risk of dependence or addiction with Ofran?

Official regulatory studies have concluded that Ondansetron is not associated with a significant risk for abuse or dependence. This finding is noted in the drug’s regulatory documentation.

Q: What should I do if I accidentally miss a dose of Ofran?

Patient leaflets generally state that if a dose is missed and there are no symptoms, the next scheduled dose is typically taken as normal. If a dose is missed and symptoms occur, patient information provides general guidance for taking a dose as soon as possible, though the specific course of action is determined by the prescribing health professional.

Q: Can Ofran be crushed or split?

The oral tablet formulation of Ofran should generally be swallowed whole and is not meant to be crushed, chewed, or split. Rapidly dissolving forms (ODTs) are placed on the tongue to dissolve quickly.

Q: Is Ofran a controlled substance?

Official classification defines Ofran as a Human Prescription Drug. Its low risk for dependence or abuse means it is not generally scheduled or tracked as a controlled substance.

Q: Can Ofran cause trouble sleeping?

Trouble sleeping (insomnia) is listed in the official product information as a potential side effect of the medication.

Q: Does Ofran affect kidney function?

Official clinical pharmacology data indicates that no dosage adjustment is typically required for patients with kidney problems.

Q: Is it normal to feel a change in appetite while on Ofran?

Official reports indicate that loss of appetite has been cited as a possible adverse reaction associated with Ofran use.

Q: What are the documented signs of Ofran overdose?

Regulatory documents list several signs of overdose, including severe constipation, hypotension (low blood pressure), and visual disturbances. The most serious risk is severe heart rhythm abnormalities such as QT interval prolongation.

Q: Has Ofran been recalled or subject to any safety alerts?

Yes, official safety communications were issued regarding a specific dosage form. The FDA previously worked to remove the 32 mg single intravenous (IV) dose from the market due to the potential for serious cardiac risks.

Q: Does Ofran interact with common over-the-counter cold medicines?

Official interaction guidance advises caution with medications that affect serotonin levels or heart rhythm. Many common cold and flu remedies contain ingredients in these drug classes, which may interact with Ofran.

Q: Is Ofran safe to use with high blood pressure medication?

Ofran’s labeling notes that it can cause a decrease in blood pressure (hypotension) and changes in heart rhythm. Caution and monitoring are advised when used with other medications that affect the heart or its rhythm.

Q: Why does the packaging for Ofran have a specific warning?

Official warnings are in place primarily because Ofran can cause a change in heart rhythm called QT interval prolongation. This specific warning manages the risk of a rare but potentially fatal arrhythmia called Torsade de Pointes.

Q: Is Ofran commonly used in other countries?

The active ingredient, Ondansetron, is listed by the World Health Organization (WHO) on its Model List of Essential Medicines, confirming its global recognition and use in healthcare systems.

How should Ofran be stored and disposed of?

How to Store and Dispose of Ofran

The storage and disposal of Ofran (Ondansetron) must strictly follow official regulatory guidelines to maintain potency and ensure safety.

Storage Requirements

Formulation Required Conditions
Oral Forms (Tablets/Solution) Store at Controlled Room Temperature (20 C to 25 C) in a tightly closed container. Protect from excess heat, moisture, and light.
Injection Store at Controlled Room Temperature or in a refrigerator. Protect vials from light by keeping them in the outer carton.

All forms of Ofran must be kept out of the sight and reach of children.

Handling and Stability

For the injection, specific stability periods apply after dilution, typically requiring use within 24 to 48 hours. The oral solution must be discarded one month after the first opening. Avoid mixing the injection with incompatible solutions, as a precipitate may form.

Disposal Instructions

Unused or expired Ofran must be disposed of in accordance with local requirements. The preferred method is using a drug take-back program. If household disposal is necessary, the medicine must be mixed with an undesirable substance (e.g., dirt or coffee grounds) and sealed in a container before being thrown in the trash. Ofran is not on the FDA's flush list and should not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ofran found in:

A-Z Index: